- Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsRetatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday. The filing…Endpoints · 1d ago↗ source
- Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buyRoche has offered some insight into how it is using AI, from drug discovery to token use. AI has already contributed to “a significant increase in new molecules” in its pipeline, CEO Thomas Schin…Endpoints · 1d ago↗ source
- STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefitOn analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.